The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
60 Degrees Pharmaceuticals 9-Day RSI Related Terms
SXTP vs GLMD, FBLG, CELZ: 9-Day RSI Comparison
For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
60 Degrees Pharmaceuticals 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where 60 Degrees Pharmaceuticals's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
60 Degrees Pharmaceuticals (SXTP) has a 9-Day RSI of 66.66 as of Jul. 03, 2026. According to the industry distribution chart, 60 Degrees Pharmaceuticals ranks #1159 out of 1422 companies in the Biotechnology industry, placing it in the top 81.5%.
Is 60 Degrees Pharmaceuticals' 9-Day RSI too high?
60 Degrees Pharmaceuticals' current 9-Day RSI is 66.66. The Biotechnology industry median 9-Day RSI is 51.47. 60 Degrees Pharmaceuticals' value of 66.66 is 29.5% above this industry median. Based on the distribution chart, 60 Degrees Pharmaceuticals ranks #1159 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' 9-Day RSI compare to GLMD and FBLG?
According to the Biotechnology industry distribution chart, 60 Degrees Pharmaceuticals ranks #1159 out of 1422 companies for 9-Day RSI. This places 60 Degrees Pharmaceuticals in the lower half of its industry. The industry median 9-Day RSI is 51.47. 60 Degrees Pharmaceuticals' value of 66.66 is 29.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 51.47, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 60 Degrees Pharmaceuticals's current 9-Day RSI of 66.66 is 29.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 51.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 60 Degrees Pharmaceuticals's current 9-Day RSI is 66.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.05, compared to a current price of $1.75 — trading 14.6% below its estimated fair value. The current 9-Day RSI is 66.66 and 29.5% above the Biotechnology industry median of 51.47. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current 9-Day RSI is 66.66 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.75 is trading 14.6% below its estimated GF Value™ of $2.05.
GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SXTP:
9-Day RSI: 66.66
GF Value™: $2.05 vs. price of $1.75 (14.6% below fair value)
Industry Position: 29.5% above the Biotechnology median (#1159 of 1422)
No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score
Get the complete analysis for SXTP
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTP has been successfully added to your 